---
title: "Tumor Ablation Market worth $1.89 billion by 2031 - Exclusive Report by MarketsandMarkets™"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294724565.md"
description: "In Delray Beach, Florida, as of August 3, 2026, industry analysts at MarketsandMarkets™ have forecasted that the Tumor Ablation Market is set to grow significantly, with expectations for it to reach $1.89 billion by 2031, up from $1.10 billion in 2026. This represents a Compound Annual Growth Rate (CAGR) of 11.4% over the forecast period. The report includes in-depth analysis presented in 300 market data tables and 50 figures for detailed insights into this market sector."
datetime: "2026-08-03T17:46:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294724565.md)
  - [en](https://longbridge.com/en/news/294724565.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294724565.md)
generator: "portal-rs"
---

# Tumor Ablation Market worth $1.89 billion by 2031 - Exclusive Report by MarketsandMarkets™

In Delray Beach, Florida, as of August 3, 2026, industry analysts at MarketsandMarkets™ have forecasted that the Tumor Ablation Market is set to grow significantly, with expectations for it to reach $1.89 billion by 2031, up from $1.10 billion in 2026. This represents a Compound Annual Growth Rate (CAGR) of 11.4% over the forecast period. The report includes in-depth analysis presented in 300 market data tables and 50 figures for detailed insights into this market sector.

### Related Stocks

- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IXJ.AU](https://longbridge.com/en/quote/IXJ.AU.md)

## Related News & Research

- [RenovoRx highlights Phase III TIGeR-PaC sub-study showing 51% tumor-site gemcitabine extraction with TAMP delivery](https://longbridge.com/en/news/296914646.md)
- [US-Canada beef is heating up — and the market is already picking winners and losers](https://longbridge.com/en/news/296892283.md)
- [Lytix says FDA clears Phase III trial plan for ruxotemitide plus pembrolizumab in high-risk melanoma](https://longbridge.com/en/news/297124839.md)
- [Erasca says FDA grants fast-track status to ERAS-0015 for metastatic pancreatic cancer](https://longbridge.com/en/news/296784766.md)
- [Celltrion Seeks Korean Approval for Keytruda Biosimilar CT-P51 After Positive Trial](https://longbridge.com/en/news/296711932.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**